Summary
Nephrotic syndrome is defined as proteinuria sufficiently severe to result in hypoalbuminaemia, oedema and hyperlipidaemia. The early modern history of this illness was characterised by the serendipitous development of renal biopsy technique at approximately the same time as the use of corticosteroids for nephrotic syndrome. The coincidence of these events set the stage for evaluating therapeutic response to corticosteroids and cytotoxic agents in relation to renal histology and ultimate clinical outcome.
The International Study of Kidney Disease in Children (ISKDC) was initiated in the 1960s as a multicentre study examining these relationships in children. Over the next decade this study, as well as contributions from other investigators, helped define optimum therapy for these children. It was determined that a child with nephrotic syndrome under the age of 6 years, who did not present with hypertension, azotaemia, hypocomplementaemia or signs of systemic illness, had an approximately 85% chance of responding to corticosteroid therapy. If only those children who had minimal change histology on biopsy were considered, 94% responded. The original regimen which is still used today, was 60 mg/m2 bsa/day prednisone administered on a 3 times per day dosage schedule for 4 weeks, followed by an additional 4 weeks of therapy at a dose of 40 mg/m2 bsa given as a single oral dose every other day.
Of those who respond roughly one-third will have no relapses, while almost half will have frequent relapses (⩾ 2 in 6 months) and the rest will have infrequent relapses. Patients in relapse are treated as at presentation but are usually converted to the 40 mg/m2 bsa dose when the urine has been free of protein for 3 days, and are then tapered off or maintained on this dose for several weeks, depending on the individual’s history of relapses and incidence of side effects from corticosteroids.
For those children who are suffering frequent relapses and severe corticosteroid side effects (e.g. growth failure, morbid obesity, aseptic necrosis of bone), cytotoxic agents were identified as providing long term remission. After inducing remission with conventional corticosteroid dosages, cyclophosphamide is administered at a dose of 2 mg/kg/day given as a single dose for 8 weeks. This regimen was shown to lead to approximately 70% of patients being in remission 2 years after completion of this course of therapy. Chlorambucil given at a dose of 0.2 mg/kg/day as a single oral dose has been equally efficacious. A subgroup of the frequently relapsing patients, termed steroid-dependent (defined as relapsing while tapering prednisone or very shortly after discontinuing prednisone) are less likely to benefit from cytotoxic therapy, with only 30% being in remission 2 years after therapy is completed. In addition, children with histological lesions other than minimal change (e.g. focal segmental glomerulosclerosis) are less likely to respond to corticosteroids or cytotoxic agents.
Two other agents have been used for treatment of nephrotic syndrome. In steroid-dependent or -resistant children oral cyclosporin 7 mg/kg/day kept serum trough concentrations between 100 and 200 μg/L. Many of these patients relapsed when therapy was discontinued. Chlormethine (nitrogen mustard) has also been effective in producing long relapse-free intervals when used at a dose of 0.1 mg/kg/day, given as a single intravenous dose for 4 days.
The risks of these medications are discussed, focusing on leucopenia, infertility and risk of subsequent malignancy. At the dosages noted above, leucopenia is not required for the therapeutic effect and does not usually prevent the completion of therapy, infertility is rare, and at present the question of increased risk of malignancy due to the use of cytotoxic agents remains unanswered.
Similar content being viewed by others
References
Abiko T, Onodera I, Sekino H. The effect of a synthetic thymosin-x fragment on the inhibition of E-rosette formation by the serum of a patient with nephrotic syndrome. Chemical and Pharmaceutical Bulletin 27: 3171–3175, 1979
Adlkofer F, Hain H, Meinhold H, Kraft D, Ramsden D, et al. Thyroid function in patients with proteinuria and normal or increased serum creatinine concentration. Acta Endocrinologica 102: 367–376, 1983
Ahuja AS, Wright M. MMR and the nephrotic syndrome. British Medical Journal 299: 796, 1989
Alfiler CA, Roy LP, Doran T, Sheldon A, Bashir H. HLA DRW7 and steroid responsive nephrotic syndrome of childhood. Clinical Nephrology 14: 71–74, 1980
Allon M, Campbell WG, Nasr SA, Bourke E, Stoute J, et al. Minimal change glomerulonephropathy and interstitial infiltration with mycosis fungoides. American Journal of Medicine 84: 756–759, 1988
Alwall N. Aspiration biopsy of the kidney. Acta Medica Scandinavica CXLIII: 430–435, 1952
Anderson DC, York TL, Rose G, Smith CW. Assessment of serum factor B, serum opsonins, granulocyte chemotaxis, and infection in nephrotic syndrome of children. Journal of Infectious Diseases 140: 1–11, 1979
APN (Arbeitsgemainschaft fur Padiatrische Nephrologie). Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. Lancet 1: 401, 1979
APN (Arbeitsgemainschaft fur Padiatrische Nephrologie). Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. New England Journal of Medicine 306: 451–454, 1982
Arneil GC. 164 children with nephrosis. Lancet 2: 1103, 1961
Averbuch SD, Austin HA, Sherwin SA, Antonovych T, Bunn PA, et al. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. New England Journal of Medicine 310: 32–35, 1984
Baliah T, Park BH, Neter E. Low ASO titers and abnormal immunoglobulin levels in minimal lesion nephrotic syndrome in children. Federation Proceedings 36: 1055, 1977
Ballow M, Kennedy TL, Gaudio KM, Siegel NJ, McLean RH. Serum hemolytic factor D values in children with steroid responsive idiopathic nephrotic syndrome. Journal of Pediatrics 100: 192–196, 1982
Barness LA, Moll GH, Janeway CA. Nephrotic syndrome. Pediatrics 5: 486–503, 1950
Barratt TM, Soothill JF. Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet 2: 30, 1970
Barratt TM, Bercowsky A, Osofsky SG, Soothill JF, Kay R. Cyclophosphamide treatment in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet 2: 30, 1970
Barratt TM, Bercowsky A, Osofsky SG, Soothill JF, Kay R. Cyclophosphamide treatment in steroid-sensitive nephrotic syndrome of childhood. Lancet 1: 33, 1975
Bernard DB. Extrarenal complications of the nephrotic syndrome. Kidney International 33: 1184–1202, 1988
Berns JS, Gaudio KM, Krassner LS, Anderson FP, Durante D, et al. Steroid-responsive nephrotic syndrome of childhood: a long-term study of clinical course, histopathology, efficacy of cyclophosphamide therapy, and effects on growth. American Journal of Kidney Diseases 9: 108–114, 1987
Bhasin HK, Abuelo JG, Nayak R, Esparza AR. Mesangial proliferative glomerulonephritis. Laboratory Investigation 39: 21–29, 1978
Blumberg RW, Cassady HA. Effect of measles on the nephrotic syndrome. American Journal of Diseases in Children 73: 151–166, 1947
Boulton-Jones JM, Simpson S. Immunological studies of minimal change nephropathy. British Medical Journal 280: 291–292, 1980
Brandis M, Burghard R, Leititis J, Zimmerhacki B, Hidebrandt F, et al. Cyclosporin A for treatment in nephrotic syndromes. Abstract. Pediatric Nephrology 1: C42, 1987
Branellec A, Laurent J, Heslan JM, Bruneau C, Lagrue G. A transient monocyte defective function in idiopathic nephrotic syndrome (lipoid nephrosis). International Urology and Nephrology 20: 421–428, 1988
Brodovsky HS, Samuels ML, Migliore PJ. Chronic lymphocytic leukemia, Hodgkins disease and the nephrotic syndrome. Archives of Internal Medicine 121: 71–75, 1968
Brown EA, Sampson B, Muller BR, Curtis JR. Urinary iron loss in the nephrotic syndrome: an unusual cause of iron deficiency with a note on urinary copper losses. Postgraduate Medical Journal 160: 125–128, 1984
Brown EA, Upadhyaya K, Hayslett JP, Kashgarian M, Siegel NJ. The clinical course of mesangial proliferative glomerulonephritis. Medicine 58: 295–303, 1979
Cameron JS. Chlorambucil and leukemia. New England Journal of Medicine 296: 49, 1977
Cameron JS. The nephrotic syndrome and its complications. American Journal of Kidney Diseases 10: 157–171, 1987
Cameron JS, Chantier C, Ogg CS, White RHR. Long-term stability of remission in nephrotic syndrome after treatment with cyclophosphamide. British Medical Journal 4: 7–11, 1974
Capodicasa G, DeSanto NG, Nizzi F, Giordano C. Cyclosporin A in nephrotic syndrome in childhood: 14 month experience. International Journal of Pediatric Nephrology 7: 69–72, 1986
Cartwright GE, Gubler CJ, Wintrobe MM. Studies in copper metabolism XI: copper and iron metabolism in the nephrotic syndrome. Journal of Clinical Investigation 33: 685–698, 1954
Chapman S, Taube D, Brown Z, Williams DG. Impaired lymphocyte transformation in minimal change nephropathy in remission. Clinical Nephrology 18: 34–38, 1982
Chasis H, Goldring W, Baldwin DS. Effect of febrile plasma, typhoid vaccine and nitrogen mustard on renal manifestations of human glomerulonephritis. Proceedings of the Society for Experimental Biology and Medicine 71: 565–567, 1949
Chasis H, Goldring W, Baldwin DS. The effect of nitrogen mustard on renal manifestations of human glomerulonephritis. Journal of Clinical Investigation 29: 804, 1950
Cheng IKP, Jones BM, Chan PCK, Chan MK. The role of soluble immune response suppressor lymphokine in the prediction of steroid responsiveness in idiopathic nephrotic syndrome. Clinical Nephrology 32: 168–172, 1989
Cheviakoff S, Calamera JC, Morgenfeld M, Mancini RE. Recovery of spermatogenesis in patients with lymphoma after treatment with chlorambucil. Journal of Reproduction and Fertility 33: 155–157, 1972
Chisari FV. Immunoregulatory properties of human plasma in very low density lipoproteins. Journal of Immunology 119: 2129–2136, 1977
Chiu J, McLaine PN, Drummond KN. A controlled prospective study of cyclophosphamide in relapsing, corticosteroid-response, minimal-lesion nephrotic syndrome in childhood. Journal of Pediatrics 82: 607–613, 1973
Choonara IA, Heney D, Meadow SR. Low dose prednisolone in nephrotic syndrome. Archives of Disease in Childhood 64: 610–621, 1989
Churg J, Habib R, White RHR. Pathology of the nephrotic syndrome in children. Lancet 1: 959, 1970
Cohen AH, Border WA, Glassock RJ. Nephrotic syndrome with glomerular mesangial IgM deposits. Laboratory Investigation 38: 610–619, 1978
Coldbeck JH. Experience with alkylating agents in the treatment of children with the nephrotic syndrome. Medical Journal of Australia 2: 987–989, 1963
Comp PC. Clinical implications of the protein C/protein S system. Annals of the New York Academy of Sciences 509: 149–155, 1987
Curtiss LK, Edgington TS. Regulatory serum lipoproteins: regulation of lymphocytic stimulation by a species of low density lipoprotein. Journal of Immunology 116: 1452–1458, 1976
Ellis D. Anemia in the course of the nephrotic syndrome secondary to transferrin depletion. Journal of Pediatrics 90: 953–955, 1977
Etteldorf JN, Roy S, Summitt RL, Sweeney NJ, Wall HP, et al. Cyclophosphamide in the treatment of idiopathic lipoid nephrosis. Journal of Pediatrics 70: 758–766, 1967
Etteldorf JN, West CD, Pitcock JA, Williams DL. Gonadal function, testicular histology, and meiosis following cyclophosphamide therapy in patients with nephrotic syndrome. Journal of Pediatrics 88: 206–212, 1976
Eyres K, Mallick NP, Taylor G. Evidence for cell-mediated immunity to renal antigens in minimal-change nephrotic syndrome. Lancet 1: 1158, 1976
Farnsworth EB. Metabolic changes associated with administration of adrenocorticotropin in the nephrotic syndrome. Proceedings of the Society for Experimental Biology and Medicine 74: 60–62, 1950
Fodor P, Saitua MT, Rodriguez E, Gonzalez B, Schlesinger L. T cell dysfunction in minimal-change nephropathy. American Journal of Diseases of Children 136: 713–717, 1982
Freedman P, Peters JH, Kark RM. Localization of gamma globulin in the diseased kidney. Archives of Internal Medicine 105: 524–535, 1960
Fujisawa S, Miyazaki R, Fukunishi Y, Shimizu S, Okuda R, et al. Long-term follow-up study of idiopathic nephrotic syndrome in childhood. Annales Paediatrici Japonici 25: 24–35, 1979
Galan E, Maso C. Needle biopsy in children with nephrosis. Pediatrics 20: 610–625, 1957
Garin EH, Orak JH, Hiott KL, Sutherland MS. Cyclosporine therapy for steroid-resistant nephrotic syndrome. American Journal of Diseases of Children 142: 985–988, 1988
Garin EH, Pryor ND, Fennell RS, Richard G A. Pattern of response to prednisone in idiopathic, minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy. Journal of Pediatrics 92: 304–308, 1978
Gebhardt DOE. The embryolethal and teratogenic effects of cyclophosphamide on mouse embryos. Teratology 3: 273–278, 1970
Giangiacomo J, Cleary TG, Cole BR, Hoffsten P, Robson AM. Serum immunoglobulins in the nephrotic syndrome. New England Journal of Medicine 293: 8–12, 1975
Goldstein DA, Uda Y, Kurokawa K, Massry SC. Blood levels of 25-hydroxy vitamin D in nephrotic syndrome. Annals of Internal Medicine 87: 664–667, 1977
Greenberg LH, Verdes P, Tanaka KR. Congenital anomalies probably induced by cyclophosphamide. Journal of the American Medical Association 188: 423–426, 1964
Grupe WE. Chlorambucil in steroid-dependent nephrotic syndrome. Journal of Pediatrics 82: 598–606, 1973
Grupe WE. Cytotoxic drugs for nephrotic syndrome. New England Journal of Medicine 307: 313, 1982
Grupe WE, Makker SP, Ingelfinger JR. Chlorambucil treatment of frequently relapsing nephrotic syndrome. New England Journal of Medicine 295: 746–749, 1976
Habib R, Kleinknecht C. The primary nephrotic syndrome of childhood: classification and clinicopathologic study of 406 cases. Pathology Annual 6: 417–474, 1971
Habib R, Kleinknecht C, Gubler MC, Levy M, Guillot M, et al. Pronostico de la nefrosis. Boletino Medical Hospital Infantil (Mexico City) 38: 447–455, 1981
Hardwicke J, Soothill JF, Squire JR, Holti G. Nephrotic syndrome with pollen hypersensitivity. Lancet 1: 500–502, 1959
Heslan JM, Lautric P, Intrater L, Blanc C, Lagrue G, et al. Impaired IgG synthesis in patients with the nephrotic syndrome. Clinical Nephrology 18: 144–147, 1982
Hinoshita F, Noma T, Tomura S, Shiigari T, Yata J. Decreased production and responsiveness of interleukin 2 in lymphocytes of patients with nephrotic syndrome. Nephron 54: 122–126,1990
Hisanaga S, Kawagoe H, Yamamoto Y, Kuroki N, Fujimoto S, et al. Nephrotic syndrome associated with recombinant interleukin-2. Nephron 54: 277–278, 1990
Hyman LR, Burkholder PM. Focal sclerosing glomerulopathy with segmental hyalinosis: a clinicopathological analysis. Laboratory Investigation 28: 533–544, 1973
Iitaka K, West CD. A serum inhibitor of blastogenesis in idiopathic nephrotic syndrome transferred by lymphocytes. Clinical Immunology and Immunopathology 12: 62–71, 1979
Inage Z, Wada N, Kikkawa Y, Inami H, Hirose H, et al. Suppressor T-lymphocyte dysfunction in MCNS: role of the H2 histamine receptor-bearing suppressor T lymphocytes. Clinical Nephrology 33: 20–24, 1990
Ingelfinger JR, Link DA, Davis AF, Grupe WE. Serum immunoglobulins in idiopathic minimal change nephrotic syndrome. New England Journal of Medicine 294: 50–51, 1976
ISKDC (International Study of Kidney Disease in Children). Controlled trial of azathioprine in children with nephrotic syndrome. Lancet 1: 7654, 1970
ISKDC (International Study of Kidney Disease in Children). Ten years of activity: a report for the International Study of Kidney Disease in Children. In Batsford SR et al. (Eds) Glomerulo-nephritis, pp. 201–209, John Wiley & Sons Inc., New York, 1977
ISKDC (International Study of Kidney Disease in Children). Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney International 13: 159–165, 1978
ISKDC (International Study of Kidney Disease in Children). Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. Kidney International 20: 765–771, 1981
Iversen P, Brun C. Aspiration biopsy of kidney. American Journal of Medicine 11: 324–330, 1951
Janeway CA, Moll GH, Armstrong SH, Wallace WM, Hallman N, et al. Diuresis in children with nephrosis: comparison of response to injection of normal human serum albumin and to infection, particularly measles. Transactions of the Association of American Physicians 61: 108–111, 1948
Jensen H. Plasma protein and lipid pattern in the nephrotic syndrome. Acta Medica Scandinavica 182: 465–473, 1967
Kano K, Nonoda A, Yoneshima H, Suda T. Serum concentrations of 25-hydroxy-vitamin D and 24, 25 dihydroxy vitamin D in patients with various types of renal disease. Clinical Nephrology 14: 274–279, 1980
Kashtan C, Melvin T, Kim Y. Long-term follow-up of patients with steroid-dependent, minimal change nephrotic syndrome. Clinical Nephrology 29: 79–85, 1988
Keown PA. Emerging indications for the use of cyclosporin in organ transplantation and autoimmunity. Drugs 40: 315–325, 1990
Kerpen HO, Bhat JG, Kantor R, Gauthier B, Schacht RG, et al. Lymphocyte sub-population in minimal change nephrotic syndrome. Clinical Immunology and Immunopathology 14: 130–136, 1979
Kleinknecht C, Guessy P, Lenoir G, Broyer M. High-cost benefit of chlorambucil in frequently relapsing nephrosis. New England Journal of Medicine 296: 48, 1977
Kramer P, Kate FWJT, Bijnen AB, Jeekel J, Weimar W. Recombinant leucocyte interferon a induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1: 989–990, 1984
Krensky AM, Ingelfinger JR, Grupe WE. Peritonitis in childhood nephrotic syndrome. American Journal of Diseases of Children 136: 732–736, 1982
Kuis W, deKraker J, Kingten RH, Donckerwolcke RA, Voute PA. Acute lymphoblastic leukemia after treatment of nephrotic syndrome with immunosuppressive drugs. Helvetica Pediatrica Acta 31: 91–95, 1976
Kuzemko JA. Measles vaccination and the nephrotic syndrome. British Medical Journal IV: 665–666, 1972
Lagrue G, Pech MA, Branellec AI, Heslan JM, Rostoker G, et al. Increased interleukin-2 levels in lymphocyte culture supernatants from patients with idiopathic nephrotic syndrome. In Gubler MC et al. (Eds) Progress in basement membrane research: renal and related aspects in health and disease, pp. 281–284, John Libbey Eurotext Ltd, 1988
Lagrue G, Xheneumont X, Branellec A, Hirbec G, Weil B. A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome. Biomedicine 23: 37–40, 1975
Lange K, Ahmed U, Seligson G, Grover A. Depression of endostreptosin, streptolysin O, and streptozyme antibodies in patients with idiopathic nephrosis with and without nephrotic syndrome. Clinical Nephrology 15: 279–285, 1981
Lau SO, Boch GH, Edson JR, Michael AF. Saggital sinus thrombosis in the nephrotic syndrome. Journal of Pediatrics 97: 948–950, 1980
Laurent J, Lagrue G. Dietary manipulation for idiopathic nephrotic syndrome. Allergy 44: 599–603, 1989
Lauson HD, Forman CW, McNamara H, Mattar G, Barnett HL. Effect of corticotropin (ACTH) on glomerular permeability to albumin and on blood antidiuretic hormone concentration in children with the nephrotic syndrome. American Journal of Diseases of Children 83: 87–90, 1952
Lawler W, Williams G, Tarpey P, Mallick NP. IgM associated primary diffuse mesangial proliferative glomerulonephritis. Journal of Clinical Pathology 33: 1029–1038, 1980
Lawson D, Montcrieff A, Payne WW. Forth years of nephrosis in childhood. Archives of Diseases of Childhood 35: 115–126, 1960
Lentz RD, Bergstein J, Steffes MW, Brown DR, Prem K, et al. Postpubertal evaluation of gonadal function following cyclophosphamide therapy before and during puberty. Journal of Pediatrics 91: 385–394, 1977
Levin M, Gascoine P, Turner MW, Barratt MT. A nightly cationic protein in plasma and urine of children with steroid-responsive nephrotic syndrome. Kidney International 36: 867–877, 1989
Levinsky RS, Malleson PN, Barratt TM, Soothill JF. Circulating immune complexes in steroid responsive nephrotic syndrome. New England Journal of Medicine 300: 126–129, 1978
Lewis MA, Baildom EM, Davis N, Houston IB, Postlethwaite RJ. Nephrotic syndrome: from toddlers to twenties. Lancet 1: 255–259, 1989
Lin CY, Hsu HC. Histopathological and immunological studies in spontaneous remission nephrotic syndrome after intercurrent measles infection. Nephron 42: 110–115, 1986
Mallick NP, Williams G, McFarlane H, Orr WM, Taylor G, et al. Cell-mediated immunity in nephrotic syndrome. Lancet 1: 507–509, 1972
Mansfield LE, Trygstad CW, Ajugwo RE, Heiner DC. Serum concentrations of immunoglobulins E and G and a2-macroglobulin in childhood renal disease. Journal of Allergy and Clinical Immunology 66: 227–232, 1980
Matsumoto K. Decreased production of interleukin-1 by mono-cytes from patients with lipoid nephrosis. Clinical Nephrology 31: 292–296, 1989
McLean RH, Forsgren A, Bjorksten B, Kim Y, Quie PG, et al. Decreased serum factor B concentration associated with decreased opsonization of Escherichia coli in the idiopathic nephrotic syndrome. Pediatric Research 15: 697, 1977
McLeod T, McKinney C, Zilleruelo C, Sanberg D, Strauss J. Inhibition of lymphocyte blastogenesis by serum β-lipoprotein from minimal change nephrotic syndrome (MCNS) patients. Pediatric Research 15: 697, 1981
Meadow SR, Sarsfield JK, Scott DG, Rajah SM. Steroid-responsive nephrotic syndrome and allergy: immunologica studies. Archives of Disease in Childhood 56: 517–524, 1981
Meltzer AV, Keim HL, Larogh JH, Sealey JE, Jan KM, et al. Nephrotic syndrome vasoconstriction and hypervolemic types indicated by renin-sodium profiling. Annals of Internal Medicine 91: 688–696, 1979
Melvin T, Sibley R, Michael AF. Nephrotic syndrome in pediatric nephrology. In Mendoza S et al. (Eds) Pediatric nephrology, pp. 191–230, Churchill Livingstone, New York, 1984
Meyrier A, Simon P, Perret G, Condamin MC. Remission of idiopathic nephrotic syndrome after treatment with cyclosporin A. British Medical Journal 292: 789–792, 1986
Menchaca JA, Lefkowitz S. Hyperlipoproteinemia, cellular immunity, and nephrotic syndrome. Lancet 1: 1084–1085, 1980
Minchin MA, Turner KJ, Bower GD. Lymphocyte blastogenesis in nephrotic syndrome. Clinical and Experimental Immunology 42: 241–246, 1981
Mongeau JG, Corneille L, Robitaille P, O’Regan S, Pelletier M. Primary nephrosis in childhood associated with focal glomerular sclerosis: is long-term prognosis that severe? Kidney International 20: 743–746, 1981
Mouzon-Cambon de A, Bouissou F, Dutau G, Barthe PH, Parra MT, et al. HLA DR7 in children with idiopathic nephrotic syndrome: correlation with atopy. Tissue Antigens 17: 518–524, 1981
Muehrcke RC, Kark RM, Pirani CL. Biopsy of the kidney in the diagnosis and management of renal disease. New England Journal of Medicine 253: 537–546, 1955
Muller W, Brandis M. Acute leukemia after cytotoxic treatment for non-malignant disease of childhood: a case report and review of the literature. European Journal of Pediatrics 136: 105–108, 1981
Murnaghan K, Vasmant D, Bensman A. Pulse methylprednisolone therapy in severe idiopathic childhood nephrotic syndrome. Acta Paediatrica Scandinavica 73: 733–739, 1984
Nagata K, Platt JL, Michael AF. Interstitial and glomerular immune cell populations in idiopathic nephrotic syndrome. Kidney International 25: 88–93, 1983
Nagata K, Takahashi Y, Waga S, Fujita MJ, Kuronuma T, et al. Monocyte function in idiopathic nephrotic syndrome in childhood. Tohoku Journal of Experimental Medicine 135: 413–417, 1981
Nash MA, Greifer I, Oling H, Bernstein J, Bennett B, et al. The significance of focal sclerotic lesions of glomeruli in children. Journal of Pediatrics 101: 411–414, 1976
Newman WJ, Tisher CC, McCoy RC, Gunnells JC, Krueger RP, et al. Focal glomerular sclerosis: contrasting clinical patterns in children and adults. Medicine 55: 67–86, 1976
Ngu JL, Barratt TM, Soothill JF. Immunoconglutinin and complement changes in steroid sensitive relapsing nephrotic syndrome of children. Clinical and Experimental Immunology 6: 109–116, 1970
Niaudet P, Tete MJ, Habib R, Broyer M. Cyclosporin A in the treatment of idiopathic nephrosis in children. Pediatric Nephrology 1: C12, 1987
Noss G, Bachmann HJ, Olbing H. Association of minimal change nephrotic syndrome (MCNS) with HLA-B8 and B13. Clinical Nephrology 15: 172–174, 1981
Nunez-Roldan A, Villechenous E, Fernandez-Andrade C, Martin-Govantes J. Increased HLD-DR7 and decreased DR2 in steroid responsive nephrotic syndrome. New England Journal of Medicine 306: 366–367, 1982
Ogg CS, Cameron JS, White RHR. The C3 component of complement (βIC-globulin) in patients with heavy proteinuria. Lancet 2: 78–81, 1968
Ohta T, Matsuda I. Lipid and apolipoprotein levels in patients with nephrotic syndrome. Clinica Chimica Acta 117: 133–134, 1981
Ooi BS, Orlina AR, Masaitis L. Lymphocytotoxins in primary renal disease. Lancet 2: 1348–1349, 1974
O’Regan D, O’Callaghan U, Dundon S, Reen DJ. HLA antigens and steroid responsive nephrotic syndrome of childhood. Tissue Antigens 16: 147–151, 1980
Pachioli R, Genova R. Long-term steroid-immunosuppressive treatment of the childhood nephrotic syndrome. Pediatrics 47: 731–736, 1971
Plager J, Stutzman L. Acute nephrotic syndrome as a manifestation of active Hodgkin’s disease. American Journal of Medicine 50: 56–66, 1971
Ponticelli C, Rivolta E. Cyclosporine in nephrotic syndrome. Nephrology. Transplantation Proceedings 20 (Suppl. 4): 253–258, 1988
Posner MR, Prout MN, Berk S. Thymoma and the nephrotic syndrome. Cancer 45: 387–391, 1980
Poston RN, Cerio R, Cameron JS. Circulating immune complexes in minimal-change nephritis. New England Journal of Medicine 298: 1089, 1978
Prasad DR, Zimmerman SW, Burkholder PM. Immunohistologic features of minimal-change nephrotic syndrpme. Archives of Pathology and Laboratory Medicine 101: 345–349, 1977
Pru C, Kjellstravel CM, Cohn RA, Vernier RL. Late recurrence of minimal lesion nephrotic syndrome. Annals of Internal Medicine 100: 69–72, 1984
Reed JC, Abidi AH, Alpers JD, Hoover RG, Robb RJ, et al. Effect of cyclosporin A and dexamethasone on interleukin receptor gene expression. Journal of Immunology 137: 150–154, 1986
Reeves WG, Cameron JJ, Johansson SGO, Ogg CS, Peters DK, et al. Seasonal nephrotic syndrome. Clinical Allergy 5: 121–137, 1975
Reimold EW, Marks JF. Hypovolemic shock complicating the nephrotic syndrome in children. Journal of Pediatrics 69: 658–660, 1966
Richter P, Calamera JC, Morgenfeld MC, Kierzenbaum AL, Lavieri JC, et al. Effect of chlorambucil on spermatogenesis in the human with malignant lymphoma. Cancer 25: 1026–1030, 1970
Riley CM. Nephrotic syndrome: effect of adrenocorticotrophic hormone. Pediatrics 7: 457–470, 1951
Rosenberg SA, Lotze MT, Murel LM, Leitman S, Chang AE, et al. Observation in the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin 2. New England Journal of Medicine 313: 1485–1492, 1985
Rothenberg MB, Heymann W. The incidence of the nephrotic syndrome in children. Pediatrics 19: 446–452, 1957
Sasdelli M, Cagnoli L, Candi P, Mandreoli M, Beltradi E, et al. Cell mediated immunity in idiopathic glomerulonephritis. Clinical and Experimental Immunology 46: 27–34, 1981
Schlesinger ER, Sultz HA, Mosher WE, Feldman JG. The nephrotic syndrome: its incidence and implications for the community. American Journal of Diseases of Children 116: 623–632, 1968
Schnaper HW, Aune TM. Identification of the lymphokine soluble immune response suppressor in urine of nephrotic children. Journal of Clinical Investigation 76: 341–349, 1985
Schnaper HW, Aune TM. Steroid-sensitive mechanism of soluble immune response suppressor production in steroid-responsive nephrotic syndrome. Journal of Clinical Investigation 79: 257–264, 1987
Schoeneman MJ, Bennett B, Greifer I. The natural history of focal segmental glomerulosclerosis with and without mesangial hypercellularity in children. Clinical Nephrology 9: 45–54, 1978
Schoeneman MJ, Spitzer A, Greifer I. Nitrogen mustard therapy in children with frequently relapsing nephrotic syndrome and steroid toxicity. American Journal of Kidney Disease 2: 526–529, 1983
Schulte-Wissermann H, Gortz W, Straub E. IgE in patients with glomerulonephritis and minimal change nephrotic syndrome. European Journal of Pediatrics 131: 105–111, 1979
Seney FD, Federgreen WR, Stein H, Kashgarian M. A review of nephrotic syndrome associated with chronic lymphocytic leukemia. Archives of Internal Medicine 146: 137–141, 1986
Shakib F, Hardwicke J, Stanworth DR, White RHR. Asymmetric depression in the serum level of IgG subclasses in patients with the nephrotic syndrome. Clinical and Experimental Immunology 28: 506–511, 1977
Shimizu B. Studies on the pathogenesis of minimal change nephrotic syndrome. Pediatric Research 14: 1012, 1980
Shotton D, Monie IW. Possible teratogenic effect of chlorambucil in a human fetus. Journal of the American Medical Association 186: 74–75, 1963
Siegel NJ, Gaudio KM, Krassner LS, McDonald BM, Anderson FP, et al. Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment. Kidney International 19: 454–459, 1981
Siegel NJ, Kashgarian M, Spargo BH, Hayslett JP. Minimal change and focal sclerotic lesions in lipoid nephrosis. Nephron 13: 125–137, 1974
Smith MD, Barratt TM, Hayward AR, Soothill SF. The inhibition of complement-dependent lymphocyte rosette formation by the sera of children with steroid-sensitive nephrotic syndrome and other renal diseases. Clinical and Experimental Immunology 21: 236–243, 1975
Sobel AT, Branellec AI, Blanc CJ, Lagrue GA. Physicochemical characterization of a vascular permeability factor produced by con A-stimulated human lymphocytes. Journal of Immunology 119: 1230–1234, 1976
Staszewski H, Kumar G, Mishriki Y. Minimal change disease as the etiology of the nephrotic syndrome in a patient with angioimmunoblastic lymphadenopathy. Medical and Pediatric Oncology 16: 206–209, 1988
Taube D, Chapman S, Brown Z, Williams DG. Depression of normal lymphocyte transformation by sera of patients with minimal change nephropathy and other forms of nephrotic syndrome. Clinical Nephrology 15: 286–290, 1981
Taylor RD, Corcoran AC. Treatment of the nephrotic syndrome with nitrogen mustard. Journal of Laboratory and Clinical Medicine 36: 996–997, 1950
Tejani A, Butt K, Trachtman H, Suthanthiran M, Rosenthal CJ, et al. Cyclosporine-induced remission of relapsing nephrotic syndrome in children. Journal of Pediatrics 111: 1056–1062, 1987
Thomson PD, Barratt TM, Stokes CR, Turner MW, Soothill JF. HLA antigens and atopic features in steroid-responsive nephrotic syndrome. Lancet 2: 765–768, 1976
Thorn GW, Forsham PH, Frawley TF, Hill SRH, Roche M, et al. The clinical usefulness of ACTH and cortisone. New England Journal of Medicine 242: 824–834, 1950
Trompeter RS, Barratt TM, Kay R, Turner MW, Soothill JF. HLA, atopy, and cyclophosphamide in steroid-responsive childhood nephrotic syndrome. Kidney International 17: 113–117, 1980
Trompeter RS, Barratt TM, Layward L. Vascular permeability factor and nephrotic syndrome. Lancet 2: 900, 1978a
Trompeter RS, Evans PR, Barratt TM. Gonadal function in boys with steroid responsive nephrotic syndrome treated with cyclophosphamide for short periods. Lancet 1: 1177–1179, 1981
Trompeter RS, Layward L, Hayward AR. Primary and secondary abnormalities of T cell subpopulations. Clinical and Experimental Immunology 34: 3881–3892, 1978b
Trompeter RS, Lloyd BW, Hicks J, White RHR, Cameron JS. Long-term outcome for children with minimal-change nephrotic syndrome. Lancet 1: 368, 1985
Varsano S, Bruderman I, Bernheim JL, Rathaus M, Griffel B. Minimal change nephropathy and malignant thymoma. Chest 77: 695–697, 1980
Vilches AR, Turner DR, Cameron JS, Ogg CS, Chantier C, et al. Significance of mesangial IgM deposition in minimal change nephrotic syndrome. Laboratory Investigation 46: 10–23, 1982
Waldherr R, Gubler MC, Levy M, Broyer H, Habib R. The significance of pure mesangial proliferation in idiopathic nephrotic syndrome. Clinical Nephrology 10: 171–179, 1978
Wall RL, Clausen KP. Carcinoma of the urinary bladder in patients receiving cyclophosphamide. New England Journal of Medicine 293: 271–273, 1975
West CD, Hong R, Holland NH. Effect of cyclophosphamide on lipoid nephrosis in the human and on aminonucleoside nephrosis in the rat. Journal of Pediatrics 68: 516–524, 1966
West CD, McAdams AJ, McConville JM, Davis NC, Holland NH. Hypocomplementemic and normocomplementemic persistent (chronic) glomerulonephritis; clinical and pathologic characteristics. Journal of Pediatrics 67: 1089–1112, 1965
White RHR, Glasgow EF, Mills RJ. Clinicopathological study of nephrotic syndrome in childhood. Lancet 1: 1353–1359, 1970
White RHR, Glasgow EF, Mills RJ. Focal glomerulosclerosis in childhood. ] In Becker EL et al. (Eds) Gomerulonephritis, pp. 231–248, John Wiley & Sons, New York, 1973
Williams SA, Makker SP, Grupe WE. Seizures: a significant side effect of chlorambucil therapy in children. Journal of Pediatrics 93: 516–518, 1978
Williams SA, Makker SP, Ingelfinger JR, Grupe WE. Long-term evaluation of chlorambucil plus prednisone in the idiopathic nephrotic syndrome of childhood. New England Journal of Medicine 302: 929–933, 1980
Yang JY, Melvin T, Sibley R, Michael AF. No evidence for a specific role of IgM in mesangial proliferation of idiopathic nephrotic syndrome. Kidney International 24: 100–106, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Melvin, T., Bennett, W. Management of Nephrotic Syndrome in Childhood. Drugs 42, 30–51 (1991). https://doi.org/10.2165/00003495-199142010-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199142010-00003